Our Pricing

Buy Wegovy UK Private Prescription: Fast Access Without NHS Delays

Published on: June 03, 2026

If you're ready to buy Wegovy UK private prescription, Cured Pharmacy offers transparent pricing from £79.00 UK-registered clinical assessments completed in under 3 minutes, and discreet next-day delivery. Unlike NHS pathways with multi-month waiting lists, our private service connects you with licensed prescribers immediately, subject to clinical suitability.

How Wegovy Works for Weight Loss

Wegovy contains semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist licensed by the MHRA for chronic weight management in adults with a BMI of 30 kg/m² or above, or 27 kg/m² with weight-related comorbidities [1]. Semaglutide mimics the natural GLP-1 hormone, slowing gastric emptying, reducing appetite, and improving glycaemic control.

In the landmark STEP 1 trial, participants receiving once-weekly semaglutide 2.4 mg achieved an average body weight reduction of 14.9% over 68 weeks, compared to 2.4% with placebo [1]. These results positioned Wegovy as one of the most effective pharmacological interventions for obesity available in the UK.

Wegovy is administered as a subcutaneous injection once weekly, with a gradual dose escalation protocol starting at 0.25 mg and increasing to the maintenance dose of 2.4 mg over 16 weeks. This titration schedule minimises gastrointestinal side effects commonly associated with GLP-1 therapies [2].

Why Choose Private Prescription Over NHS for Wegovy

The NHS provides Wegovy through specialist weight management services, but access is severely restricted by clinical commissioning group (CCG) budgets and strict eligibility criteria. Waiting times frequently exceed 12 months in many regions, and some CCGs have paused new referrals entirely due to supply constraints.

A private prescription route through a registered UK pharmacy like Cured Pharmacy eliminates waiting lists entirely. Our UK-registered prescribers assess your suitability within 24 hours, and approved prescriptions are dispensed immediately with next-day delivery available across England, Scotland, Wales, and Northern Ireland.

Private prescriptions also offer dosing flexibility. While NHS protocols may require participation in structured weight management programmes before prescribing, private pathways allow clinically appropriate patients to begin treatment promptly, subject to prescriber approval and ongoing monitoring.

Transparent Pricing Before Consultation

At Cured Pharmacy, Wegovy starts from £79.00 per pen, with pricing displayed upfront before your consultation. There are no hidden fees, and our lowest price guarantee ensures you're accessing competitive UK pricing without compromising on quality or regulatory compliance. All medicines are sourced directly from UK-licensed wholesalers and dispensed by our GPhC-registered pharmacy (9012511).

The Cured Pharmacy Private Prescription Process

Our streamlined consultation takes under 3 minutes to complete. You'll answer questions about your medical history, current medications, weight loss goals, and any contraindications. This assessment is reviewed by a UK-registered prescriber—either a GP or an independent prescribing pharmacist—who determines clinical suitability.

If approved, your prescription is sent electronically to our pharmacy team. Superintendent Pharmacist Tarun Kumar (GPhC 2233073) oversees all dispensing to ensure accuracy and compliance with MHRA guidelines. Your Wegovy pens are dispatched in 100% discreet packaging with no external branding, and tracking details are sent via SMS and email.

Follow-up consultations are included at no additional charge. Our clinical team monitors your progress, adjusts dosing as needed, and provides guidance on managing side effects or optimising treatment outcomes. This continuity of care mirrors best practices in specialist weight management clinics.

Who Can Get a Private Wegovy Prescription?

Wegovy is licensed for adults with a BMI of 30 kg/m² or higher, or 27 kg/m² with at least one weight-related condition such as type 2 diabetes, hypertension, or obstructive sleep apnoea [2]. Contraindications include personal or family history of medullary thyroid carcinoma, multiple endocrine neoplasia syndrome type 2, and severe gastrointestinal disease. Your prescriber will assess these factors during your consultation.

Wegovy vs Other Weight Loss Treatments Available in the UK

Several GLP-1 receptor agonists are now licensed for weight management in the UK, each with distinct pharmacological profiles. Wegovy (semaglutide) activates GLP-1 receptors exclusively, while newer dual agonists target both GLP-1 and GIP pathways. Understanding these differences helps patients and prescribers select the most appropriate treatment.

Saxenda (liraglutide) was the first GLP-1 therapy licensed for obesity in the UK, but requires daily injections and produces more modest weight loss—approximately 5-8% body weight reduction in clinical trials [3]. Wegovy's once-weekly dosing and superior efficacy have made it the preferred first-line injectable for most patients.

Oral medications like orlistat and combination therapies such as naltrexone/bupropion (Mysimba) remain options for patients who prefer non-injectable treatments, though clinical trial data consistently show GLP-1 therapies produce greater and more sustained weight loss [4].

Managing Side Effects and Optimising Wegovy Results

Gastrointestinal side effects—particularly nausea, vomiting, diarrhoea, and constipation—are the most commonly reported adverse events with Wegovy, affecting up to 44% of patients in the STEP trials [1]. These symptoms typically peak during dose escalation and diminish as the body adapts to treatment.

To minimise discomfort, prescribers recommend eating smaller, more frequent meals, avoiding high-fat foods, and staying well-hydrated. If nausea persists, your prescriber may slow the titration schedule or prescribe antiemetics. Most patients tolerate the maintenance dose well after the initial adjustment period.

Weight loss outcomes improve significantly when Wegovy is combined with behavioural interventions. The STEP 3 trial demonstrated that participants receiving semaglutide plus intensive behavioural therapy achieved 16% average weight reduction, compared to 14.9% with semaglutide alone [5]. Our clinical team can provide guidance on sustainable dietary changes and physical activity modifications.

Long-Term Use and Discontinuation

Wegovy is intended for chronic weight management, not short-term use. Clinical guidelines recommend continuing treatment as long as patients achieve at least 5% weight loss after 12-16 weeks and tolerate the medication well [2]. Discontinuation often leads to weight regain, so ongoing treatment and lifestyle modification are essential for sustained results.

Why Patients Choose Cured Pharmacy for Wegovy

Cured Pharmacy is a fully registered UK online pharmacy (GPhC 9012511) specialising in evidence-based treatments for weight management, sexual health, and chronic conditions. Unlike unregulated online vendors, we dispense only genuine UK-licensed medicines sourced through MHRA-approved supply chains.

Our pricing is transparent and competitive. At £79.00 per Wegovy pen, we offer some of the lowest private prescription costs in the UK, with a price-match guarantee. There are no subscription fees, hidden consultation charges, or inflated delivery costs—what you see is what you pay.

Patient reviews consistently highlight our clinical team's responsiveness and expertise. Superintendent Pharmacist Tarun Kumar personally oversees complex cases, and our prescribers are available for follow-up questions throughout your treatment journey. This level of personalised care sets us apart from larger, less accessible pharmacy chains.

Scientific References

1. Wilding, J. P. H., Batterham, R. L., Calanna, S., et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine, 384(11), 989–1002. https://doi.org/10.1056/NEJMoa2032183 [accessed 13 August 2026]
2. Medicines and Healthcare products Regulatory Agency. (2023). Wegovy 2.4 mg solution for injection in pre-filled pen: Summary of Product Characteristics. GOV.UK. https://www.gov.uk/government/organisations/medicines-and-healthcare-products-regulatory-agency [accessed 13 August 2026]
3. Pi-Sunyer, X., Astrup, A., Fujioka, K., et al. (2015). A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management. New England Journal of Medicine, 373(1), 11–22. https://doi.org/10.1056/NEJMoa1411892 [accessed 13 August 2026]
4. National Institute for Health and Care Excellence. (2023). Obesity: identification, assessment and management (CG189). NICE. https://www.nice.org.uk/guidance/cg189 [accessed 13 August 2026]
5. Wadden, T. A., Bailey, T. S., Billings, L. K., et al. (2021). Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity: The STEP 3 Randomized Clinical Trial. JAMA, 325(14), 1403–1413. https://doi.org/10.1001/jama.2021.1831 [accessed 13 August 2026]
6. NHS. (2026). Tirzepatide: a medicine to manage type 2 diabetes and treat obesity. https://www.nhs.uk/medicines/tirzepatide/ Accessed 13 August 2026.
7. NHS. (2026). Overweight and obesity in adults. https://www.nhs.uk/conditions/overweight-and-obesity/ Accessed 13 August 2026.
8. NHS England. (2026). Weight management injections. https://www.england.nhs.uk/ourwork/prevention/obesity/medicines-for-obesity/weight-management-injections/ Accessed 13 August 2026.

Information on this page is for educational purposes only and is not medical advice. All prescription treatments require clinical assessment by a UK-registered prescriber. Always consult a qualified healthcare professional before starting any new medication.